This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

Diabetic Macular Edema Market

Will Anti-VEGF Provide Better Outcomes in Diabetic Macular Edema Treatment? Discover Exclusive Insights in FMI’s Report!

Diabetic Macular Edema Market By Drug, Form, Distribution Channel & Region - Forecast 2022 – 2032

Diabetic Macular Edema Market Outlook (2022-2032)

[250 Pages Report] The global diabetic macular edema market size is expected to reach a valuation of US$ 3.7 Bn by the end of 2022, and further expand at a CAGR of 1.2% from 2022 to 2032. The market is projected to reach a valuation of ~US$ 4.2 Bn by the end of 2032. Anti-VEGF products are leading the market in terms of drugs and they held a share of about 95.5% in 2021 in the global market.

The most frequent reason for visual loss in diabetic patients is diabetic macular edema (DME). Currently, the first-line treatment for DME is vascular endothelial growth factor inhibitors (anti-VEGFs), while the second-line treatment is typically corticosteroid implants. By reducing the frequency of intravitreal injections, these implants are an efficient and safe therapeutic modality that can improve the quality of life for DME patients.

The most frequent cause of vision loss in people with diabetic retinopathy is diabetic macular edema (DME), whose incidence is rising due to the global epidemic of type II diabetes mellitus. Other biochemical processes involved in maintaining retinal vascular homeostasis are being investigated in pharmacologic research in the hopes of identifying novel therapeutic targets for conditions that are resistant to existing therapies.

Attributes

Key Statistics

Global Diabetic Macular Edema Market Estimated Size (2022E)

US$ 3.7 Bn

Projected Market Valuation (2032F)

US$ 4.2 Bn

Value-based CAGR (2022-2032)

1.2%

Collective Value Share: Top 5 Countries

71.5%

Customize this Report

Let us know your requirement to get
100% FREE customization

2017-2021 Global Diabetic Macular Edema Demand Outlook Compared To 2022-2032 Forecast

The global diabetic macular edema market held approximately 77.0% of the overall global diabetes therapeutics market, which was worth ~US$ 4.2 Bn in 2021. Sales in the global diabetic macular edema market expanded at a CAGR of 18.1% from 2017 to 2021.

Diabetes mellitus (DM) is currently a serious health emergency. According to the World Health Organization (WHO), around 422 million people worldwide have diabetes as of 2022, and the condition is directly responsible for 1.5 million annual fatalities.

In Europe, 9.2% of adults have diabetes (61 million), 1 in 3 (33%) diabetic subjects remain undiagnosed, and 1 in 11 adults have the disease. These statistics come from the International Diabetes Federation (IDF) and are based on the data from 2021. By 2045, there will be a 13% rise in disease prevalence.

For many years, grid and focused laser photocoagulation was the gold standard of treatment for DME, which was the leading cause of moderate visual loss in diabetic subjects worldwide.

However, focal/grid laser therapy is now mostly used for DME that does not involve a center, according to the European Society of Retina Specialists (EURETINA) recommendations. The use of corticosteroid implants and anti-VEGFs in intravitreal therapy has transformed the medical treatment of DME in recent years.

With growing clinical studies presenting novel therapeutic modalities for the treatment of diabetic macular edema with high patient compliance and positive treatment outcomes, the market for diabetic macular edema is expected to witness growth at a CAGR of 1.2% during the forecast period from 2022 to 2032.

Diabetic Macular Edema Market Download Report Brochure

What Are The Key Trends Pushing Sales In Diabetic Macular Edema Market?

  • Emergence of Innovative Therapeutics like Iluvien

Manufacturers operating in the diabetic macular edema market are presented with lucrative opportunities with the introduction of novel therapeutic modalities, which will aid in the suppression and management of macular edema.

Fluocinolone acetonide (FAc), a strong glucocorticoid receptor agonist, can be released continuously for up to 36 months using an intravitreal injectable non-biodegradable implant called Iluvien. Iluvien is typically used to treat DME in individuals who have previously taken a course of corticosteroids, but did not see a significant rise in ocular pressure.

A phase 3 FAME clinical trial was used to assess Iluvien's clinical effectiveness, and numerous real-world reports have supported this finding. Notably, continuous dosing guarantees treatment even in cases where follow-up consultations are missed. This is a key benefit since a variety of variables can alter the strict dose regimen necessary for the best outcomes from anti-VEGF therapy.

The FDA has currently approved Iluvien for the treatment of DME. With the emergence of innovative therapeutics, the market for diabetic macular edema is set to propel at a profitable pace in terms of growth over the forecast period.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Which Factors Are Restraining The Demand In Diabetic Macular Edema Market?

Despite the clinical advantages of anti-VEGFs, these medications call for a number of intravitreal injections and follow-up appointments, which entails substantial direct expenditures for the healthcare system, as well as large indirect expenses for patients, their families, and society as a whole.

Additionally, due to the poor compliance of patients with these therapeutic regimens, the clinical effectiveness of these treatments after their discontinuation is low.

Furthermore, the global shortage of resources for diabetic eye care may not be entirely filled by reliance on eye care specialists and limited qualified personnel. These factors are set to cumulatively pose a restrictive impact upon growth in the diabetic macular edema market over the forecast period.

Country-Wise Insights

What Makes the U.S. a Remunerative Diabetic Macular Edema Market?

“Rising Cases of Swelling in Retina due to Diabetes Will Propel Growth in the U.S.”

The U.S. held a total share of about 58.0% in 2021 in the diabetic macular edema market, and is expected to continue to experience the same growth rate throughout the forecast period. The country is currently witnessing a high prevalence of diabetic macular edema and the market is expected to be propelled with the presence of renowned players.

The prevalence of diabetic macular edema in the U.S. was 3.8% or over 746,000 people belonging to the age group of 40 years and above, according to the American Journal of Managed Care (2018). The high prevalence is set to push growth in the U.S.

How will Sales in Germany Diabetic Macular Edema Market Fare?

“Germany-based Pharmaceutical Companies to Invest in Macular Edema Vision Treatment”

Germany held a share of about 3.2% in the global diabetic macular edema market in 2021. To establish a strong position in the market for treating the growing number of eye diseases, pharmaceutical companies in the country are making huge investments in infrastructure, new technologies, and research & development activities. These factors are projected to drive the Germany market in the next decade.

Why is Demand in Australia Diabetic Macular Edema Market Burgeoning?

“Australian Companies Are Distributing New Products for DME Eye Treatment”

Australia held approximately 3.0% of share in the global market in 2021. Due to the growing need for innovative treatments for macular edema, major players are increasingly releasing their licenced products on the Australian market.

ILUVIEN (190 micrograms intravitreal implant in applicator) has been approved by the Australian Therapeutic Goods Administration (TGA), a division of the Australian Department of Health that regulates the availability of medical products, for the treatment of diabetic oedema (DME) in patients who have originally completed a course of corticosteroids, but did not have a clinically significant rise in intraocular pressure.

Alimera Sciences, Inc. made the announcement of its authorization in August 2019.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Category-Wise Insights

Which is the Highly Preferred Drug Used for Diabetic Macular Edema Treatment?

“Need for Anti-VEGF Drugs to Treat Diabetic Eye Disease Will Surge by 2032”

By drugs, the anti-VEGF segment held a share of around 95.5% in the global diabetic macular edema market in 2021. Extensive research activities by key companies and the introduction of advanced inhibitors to repress their causative effects, which may develop into a disease indication, are set to propel the segment in the evaluation period.

Which is the Most Common Form of Diabetic Macular Edema Treatment?

“Wet Macular Degeneration to Be Treated with Intravitreal Injections”

Intravitreal injections held the highest global market share of about 94.8% in 2021. Anti-VEGF therapies are commonly administered through intravitreal injections to slow down or reverse macular edema. With anti-VEGF therapies as a majorly adopted treatment modality, the intravitreal injections segment would gain traction in terms of adoption.

Which Distribution Channel Would Benefit in the Diabetic Macular Edema Industry?

“Patients Suffering from Diabetic Edema to Visit Hospitals for Quality Care”

Hospitals held a revenue share of about 49.5% in 2021 in the global market. Hospitals would dominate in terms of product distribution in the global diabetic macular edema market owing to the easy availability of trained professionals, advanced treatment modalities, and reimbursement for procedures in hospital settings.

Competitive Landscape

Key players in the diabetic macular edema market are focusing on robust research and development activities. There is currently a large clinical pipeline for treatment formulations for diabetic macular edema. Licensing and patenting of products before distribution is an essential criterion, which is separating established players from their emerging competitors.

Key instances of recent development in the market include:

  • Novartis announced in March 2022 that the European Commission had approved Beovu, a treatment for diabetic macular edema.
  • To treat age-related macular degeneration associated with subfoveal choroidal neovascularization and diabetic macular edema, Japanese pharmaceutical giant Chugai received regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) in March 2022 for Vabysmo (faricimab) for intravitreal injection (DME).

Scope Of The Diabetic Macular Edema Market Report

Attribute

Details

Estimated Market Size (2022)

US$ 3.7 Bn

Projected Market Valuation (2032)

US$ 4.2 Bn

Value-based CAGR (2022-2032)

1.2%

Forecast Period

2017-2021

Historical Data Available for

2022-2032

Market Analysis

Value (US$ Bn)

Key Regions Covered

North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa

Key Countries Covered

U.S., Canada, Brazil, Mexico, Argentina, U.K., Germany, Italy, Russia, Spain, France, BENELUX, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC Countries, North Africa, and South Africa

Key Market Segments Covered

Drug, Form, Distribution Channel, and Region

Key Companies Profiled

  • Novartis AG
  • Bayer AG
  • Allergan Plc.
  • F. Hoffmann-La Roche Ltd.
  • Alimera Sciences Inc.
  • Valeant Pharmaceuticals International, Inc. (Bausch & Lomb Inc.)
  • KalVista Pharmaceuticals
  • Genentech
  • Oxurion (fka ThromboGenics)
  • Ocugen, Inc
  • Regeneron Pharmaceuticals, Inc.
  • Clearside Biomedical
  • Daiichi Sankyo
  • Arctic Vision
  • Chugai Pharmaceutical Co., Ltd.

Report Coverage

Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives

Key Segments Covered In Diabetic Macular Edema Market Report

By Drug:

  • Anti-VEGF
    • Ranibizumab (Lucentis)
    • Aflibercept (Eylea)
  • Corticosteroid Therapies
    • Dexamethasone (Ozurdex)
    • Fluocinolone Acetonide (Iluvien)
  • Other Off-label Drugs

By Form:

  • Intravitreal Injections
  • Intravitreal Implants

By Distribution Channel:

  • Hospitals
  • Specialty Clinics
  • Mail Order Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East and Africa (MEA)

Frequently Asked Questions

The global diabetic macular edema market was valued at around US$ 3.2 Bn in 2021.

Sales in the diabetic macular edema market are set to witness a CAGR of 1.2% and be valued at around US$ 4.2 Bn by 2032.

The global diabetic macular edema market increased at 18.1% CAGR from 2017 to 2021.

The U.S., China, Germany, Japan, and Australia account for the majority of the diabetic macular edema market share and they are currently holding 71.5% of share.

The U.S. accounted for around 58.0% of share in the global diabetic macular edema market in 2021.

Novartis AG, Bayer AG, Allergan Plc., and F. Hoffmann-La Roche Ltd., are the top four manufacturers in the diabetic macular edema market.

The China diabetic macular edema market held a share of about 4.3% in 2021.

The Japan diabetic macular edema market held a share of about 3.0% in 2021.

The Germany diabetic macular edema market holds a share of around 3.2%.

Some of the key players in the diabetic macular edema market include Novartis AG, Bayer AG, Allergan Plc., F. Hoffmann-La Roche Ltd., Alimera Sciences Inc., Valeant Pharmaceuticals International, Inc. (Bausch & Lomb Inc.), KalVista Pharmaceuticals, Genentech, Oxurion (fka ThromboGenics), Ocugen, Inc, Regeneron Pharmaceuticals, Inc., Clearside Biomedical, Daiichi Sankyo, Chugai Pharmaceutical Co., Ltd., and Arctic Vision.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

    2.3. Inclusions and Exclusions

3. Key Market Trends

    3.1. Key Trends Impacting the Market

    3.2. Drug Innovation / Development Trends

4. Key Success Factors

    4.1. Promotional Strategies- By Key Manufacturers

    4.2. Key Regulations

    4.3. Value Chain Analysis

    4.4. Regulatory Impositions

    4.5. Reimbursement Scenario

    4.6. Pipeline Analysis

    4.7. PESTEL Analysis

    4.8. Porter’s Analysis

5. Market Background

    5.1. Macro-Economic Factors

        5.1.1. Global GDP Growth Outlook

        5.1.2. Global Healthcare Expenditure Outlook

        5.1.3. Global Diabetes Therapeutics Market Outlook

    5.2. Forecast Factors - Relevance & Impact

        5.2.1. Growing Geriatric Age Group Population

        5.2.2. Rising Research and Development Activities

        5.2.3. Rising Prevalence of Diabetes

        5.2.4. Emergence of New Therapeutic Drug Modalities

        5.2.5. Drug Patent and Licensing Activities

        5.2.6. Prevalence of Vision Loss

    5.3. Market Dynamics

        5.3.1. Drivers

        5.3.2. Restraints

        5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

    6.1. COVID-19 and Impact Analysis

        6.1.1. By Drug

        6.1.2. By Form

        6.1.3. By Distribution Channel

        6.1.4. By Country

    6.2. 2021 Market Scenario

7. Global Diabetic Macular Edema Market - Pricing Analysis

    7.1. Regional Pricing Analysis By Drug

    7.2. Pricing Break-up

        7.2.1. Manufacturer Level Pricing

        7.2.2. Distributor Level Pricing

    7.3. Global Average Pricing Analysis Benchmark

    7.4. Pricing Assumptions

8. Global Diabetic Macular Edema Market Demand (in Value or Size in US$ Bn) Analysis 2017–2021 and Forecast, 2022–2032

    8.1. Historical Market Value (US$ Bn) Analysis, 2017-2021

    8.2. Current and Future Market Value (US$ Bn) Projections, 2022–2032

        8.2.1. Y-o-Y Growth Trend Analysis

        8.2.2. Absolute $ Opportunity Analysis

9. Global Diabetic Macular Edema Market Analysis 2017-2021 and Forecast 2022–2032, By Drug

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Bn) Analysis By Drug, 2017 - 2021

    9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Drug, 2022 - 2032

        9.3.1. Anti-VEGF

            9.3.1.1. Ranibizumab (Lucentis)

            9.3.1.2. Afilbercept (Eylea)

        9.3.2. Corticosteroid Therapies

            9.3.2.1. Dexamethasone (Ozurdex)

            9.3.2.2. Fluocinolone Acetonide (Iluvien)

        9.3.3. Other Off-label Drugs

    9.4. Market Attractiveness Analysis By Drug

10. Global Diabetic Macular Edema Market Analysis 2017-2021 and Forecast 2022–2032, By Form

    10.1. Introduction / Key Findings

    10.2. Historical Market Size (US$ Bn) Analysis By Form , 2017 - 2021

    10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Form, 2022 - 2032

        10.3.1. Intravitreal Injections

        10.3.2. Intravitreal Implants

    10.4. Market Attractiveness Analysis By Form

11. Global Diabetic Macular Edema Market Analysis 2017-2021 and Forecast 2022–2032, By Distribution Channel

    11.1. Introduction / Key Findings

    11.2. Historical Market Size (US$ Bn) Analysis By Distribution Channel, 2017 - 2021

    11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Distribution Channel, 2022 - 2032

        11.3.1. Hospitals

        11.3.2. Specialty Clinics

        11.3.3. Mail Order Pharmacies

    11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Diabetic Macular Edema Market Analysis 2017-2021 and Forecast 2022–2032, By Region

    12.1. Introduction / Key Findings

    12.2. Historical Market Size (US$ Bn) Analysis By Region, 2017-2021

    12.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Region, 2022–2032

        12.3.1. North America

        12.3.2. Latin America

        12.3.3. Europe

        12.3.4. East Asia

        12.3.5. South Asia

        12.3.6. Oceania

        12.3.7. Middle East and Africa

    12.4. Market Attractiveness Analysis By Region

13. North America Diabetic Macular Edema Market Analysis 2017–2021 and Forecast 2022–2032

    13.1. Introduction

    13.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2017–2021

    13.3. Current and Future Market Size (US$ Bn) Analysis & Forecast By Market Taxonomy, 2022–2032

        13.3.1. By Country

            13.3.1.1. U.S.

            13.3.1.2. Canada

        13.3.2. By Drug

        13.3.3. By Form

        13.3.4. By Distribution Channel

    13.4. Market Attractiveness Analysis

        13.4.1. By Country

        13.4.2. By Drug

        13.4.3. By Form

        13.4.4. By Distribution Channel

    13.5. Market Trends

    13.6. Key Market Participants - Intensity Mapping

    13.7. Drivers and Restraints - Impact Analysis

    13.8. Country Level Analysis & Forecast

        13.8.1. U.S. Diabetic Macular Edema Market Analysis

            13.8.1.1. Introduction

            13.8.1.2. Market Analysis and Forecast By Market Taxonomy

                13.8.1.2.1. By Country

                13.8.1.2.2. By Drug

                13.8.1.2.3. By Form

                13.8.1.2.4. By Distribution Channel

        13.8.2. Canada Diabetic Macular Edema Market Analysis

            13.8.2.1. Introduction

            13.8.2.2. Market Analysis and Forecast By Market Taxonomy

                13.8.2.2.1. By Country

                13.8.2.2.2. By Drug

                13.8.2.2.3. By Form

                13.8.2.2.4. By Distribution Channel

14. Latin America Diabetic Macular Edema Market Analysis 2017–2021 and Forecast 2022–2032

    14.1. Introduction

    14.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2017–2021

    14.3. Current and Future Market Size (US$ Bn) Analysis & Forecast By Market Taxonomy, 2022–2032

        14.3.1. By Country

            14.3.1.1. Mexico

            14.3.1.2. Brazil

            14.3.1.3. Argentina

            14.3.1.4. Rest of Latin America

                14.3.1.4.1. By Country

                14.3.1.4.2. By Drug

                14.3.1.4.3. By Form

                14.3.1.4.4. By Distribution Channel

    14.4. Market Attractiveness Analysis

                14.4.1.1.1. By Country

                14.4.1.1.2. By Drug

                14.4.1.1.3. By Form

                14.4.1.1.4. By Distribution Channel

    14.5. Market Trends

    14.6. Key Market Participants - Intensity Mapping

    14.7. Drivers and Restraints - Impact Analysis

    14.8. Country Level Analysis & Forecast

        14.8.1. Mexico Diabetic Macular Edema Market Analysis

            14.8.1.1. Introduction

            14.8.1.2. Market Analysis and Forecast By Market Taxonomy

                14.8.1.2.1. By Drug

                14.8.1.2.2. By Form

                14.8.1.2.3. By Distribution Channel

        14.8.2. Brazil Diabetic Macular Edema Market Analysis

            14.8.2.1. Introduction

            14.8.2.2. Market Analysis and Forecast By Market Taxonomy

                14.8.2.2.1. By Country

                14.8.2.2.2. By Drug

                14.8.2.2.3. By Form

                14.8.2.2.4. By Distribution Channel

        14.8.3. Argentina Diabetic Macular Edema Market Analysis

            14.8.3.1. Introduction

            14.8.3.2. Market Analysis and Forecast By Market Taxonomy

                14.8.3.2.1. By Drug

                14.8.3.2.2. By Form

                14.8.3.2.3. By Distribution Channel

15. Europe Diabetic Macular Edema Market Analysis 2017–2021 and Forecast 2022–2032

    15.1. Introduction

    15.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2017–2021

    15.3. Current and Future Market Size (US$ Bn) Analysis & Forecast By Market Taxonomy, 2022–2032

        15.3.1. By Country

            15.3.1.1. Germany

            15.3.1.2. Italy

            15.3.1.3. France

            15.3.1.4. U.K.

            15.3.1.5. Spain

            15.3.1.6. BENELUX

            15.3.1.7. Russia

            15.3.1.8. Rest of Europe

        15.3.2. By Drug

        15.3.3. By Form

        15.3.4. By Distribution Channel

    15.4. Market Attractiveness Analysis

        15.4.1. By Country

        15.4.2. By Drug

        15.4.3. By Form

        15.4.4. By Distribution Channel

    15.5. Market Trends

    15.6. Key Market Participants - Intensity Mapping

    15.7. Drivers and Restraints - Impact Analysis

    15.8. Country Level Analysis & Forecast

        15.8.1. Germany Diabetic Macular Edema Market Analysis

            15.8.1.1. Introduction

            15.8.1.2. Market Analysis and Forecast By Market Taxonomy

                15.8.1.2.1. By Drug

                15.8.1.2.2. By Form

                15.8.1.2.3. By Distribution Channel

        15.8.2. Italy Diabetic Macular Edema Market Analysis

            15.8.2.1. Introduction

            15.8.2.2. Market Analysis and Forecast By Market Taxonomy

                15.8.2.2.1. By Drug

                15.8.2.2.2. By Form

                15.8.2.2.3. By Distribution Channel

        15.8.3. France Diabetic Macular Edema Market Analysis

            15.8.3.1. Introduction

            15.8.3.2. Market Analysis and Forecast By Market Taxonomy

                15.8.3.2.1. By Drug

                15.8.3.2.2. By Form

                15.8.3.2.3. By Distribution Channel

        15.8.4. U.K. Diabetic Macular Edema Market Analysis

            15.8.4.1. Introduction

            15.8.4.2. Market Analysis and Forecast By Market Taxonomy

                15.8.4.2.1. By Drug

                15.8.4.2.2. By Form

                15.8.4.2.3. By Distribution Channel

        15.8.5. Spain Diabetic Macular Edema Market Analysis

            15.8.5.1. Introduction

            15.8.5.2. Market Analysis and Forecast By Market Taxonomy

                15.8.5.2.1. By Drug

                15.8.5.2.2. By Form

                15.8.5.2.3. By Distribution Channel

        15.8.6. BENELUX Diabetic Macular Edema Market Analysis

            15.8.6.1. Introduction

            15.8.6.2. Market Analysis and Forecast By Market Taxonomy

                15.8.6.2.1. By Drug

                15.8.6.2.2. By Form

                15.8.6.2.3. By Distribution Channel

        15.8.7. Russia Diabetic Macular Edema Market Analysis

            15.8.7.1. Introduction

            15.8.7.2. Market Analysis and Forecast By Market Taxonomy

                15.8.7.2.1. By Drug

                15.8.7.2.2. By Form

                15.8.7.2.3. By Distribution Channel

16. East Asia Diabetic Macular Edema Market Analysis 2017–2021 and Forecast 2022–2032

    16.1. Introduction

    16.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2017–2021

    16.3. Current and Future Market Size (US$ Bn) Analysis & Forecast By Market Taxonomy, 2022–2032

        16.3.1. By Country

            16.3.1.1. China

            16.3.1.2. Japan

            16.3.1.3. South Korea

        16.3.2. By Drug

        16.3.3. By Form

        16.3.4. By Distribution Channel

    16.4. Market Attractiveness Analysis

        16.4.1. By Country

        16.4.2. By Drug

        16.4.3. By Form

        16.4.4. By Distribution Channel

    16.5. Market Trends

    16.6. Key Market Participants - Intensity Mapping

    16.7. Drivers and Restraints - Impact Analysis

    16.8. Country Level Analysis & Forecast

        16.8.1. China Diabetic Macular Edema Market Analysis

            16.8.1.1. Introduction

            16.8.1.2. Market Analysis and Forecast By Market Taxonomy

                16.8.1.2.1. By Drug

                16.8.1.2.2. By Form

                16.8.1.2.3. By Distribution Channel

        16.8.2. Japan Diabetic Macular Edema Market Analysis

            16.8.2.1. Introduction

            16.8.2.2. Market Analysis and Forecast By Market Taxonomy

                16.8.2.2.1. By Drug

                16.8.2.2.2. By Form

                16.8.2.2.3. By Distribution Channel

        16.8.3. South Korea Diabetic Macular Edema Market Analysis

            16.8.3.1. Introduction

            16.8.3.2. Market Analysis and Forecast By Market Taxonomy

                16.8.3.2.1. By Drug

                16.8.3.2.2. By Form

                16.8.3.2.3. By Distribution Channel

17. South Asia Diabetic Macular Edema Market Analysis 2017–2021 and Forecast 2022–2032

    17.1. Introduction

    17.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2017–2021

    17.3. Current and Future Market Size (US$ Bn) Analysis & Forecast By Market Taxonomy, 2022–2032

        17.3.1. By Country

            17.3.1.1. India

            17.3.1.2. Indonesia

            17.3.1.3. Malaysia

            17.3.1.4. Thailand

            17.3.1.5. Rest of South Asia

        17.3.2. By Drug

        17.3.3. By Form

        17.3.4. By Distribution Channel

    17.4. Market Attractiveness Analysis

        17.4.1. By Country

        17.4.2. By Drug

        17.4.3. By Form

        17.4.4. By Distribution Channel

    17.5. Market Trends

    17.6. Key Market Participants - Intensity Mapping

    17.7. Drivers and Restraints - Impact Analysis

    17.8. Country Level Analysis & Forecast

        17.8.1. India Diabetic Macular Edema Market Analysis

            17.8.1.1. Introduction

            17.8.1.2. Market Analysis and Forecast By Market Taxonomy

                17.8.1.2.1. By Drug

                17.8.1.2.2. By Form

                17.8.1.2.3. By Distribution Channel

        17.8.2. Indonesia Diabetic Macular Edema Market Analysis

            17.8.2.1. Introduction

            17.8.2.2. Market Analysis and Forecast By Market Taxonomy

                17.8.2.2.1. By Drug

                17.8.2.2.2. By Form

                17.8.2.2.3. By Distribution Channel

        17.8.3. Malaysia Diabetic Macular Edema Market Analysis

            17.8.3.1. Introduction

            17.8.3.2. Market Analysis and Forecast By Market Taxonomy

                17.8.3.2.1. By Drug

                17.8.3.2.2. By Form

                17.8.3.2.3. By Distribution Channel

        17.8.4. Thailand Diabetic Macular Edema Market Analysis

            17.8.4.1. Introduction

            17.8.4.2. Market Analysis and Forecast By Market Taxonomy

                17.8.4.2.1. By Drug

                17.8.4.2.2. By Form

                17.8.4.2.3. By Distribution Channel

18. Oceania Diabetic Macular Edema Market 2017-2021 and Forecast 2022-2032

    18.1. Introduction

    18.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2017–2021

    18.3. Current and Future Market Size (US$ Bn) Analysis & Forecast By Market Taxonomy, 2022–2032

        18.3.1. By Country

            18.3.1.1. Australia

            18.3.1.2. New Zealand

        18.3.2. By Drug

        18.3.3. By Form

        18.3.4. By Distribution Channel

    18.4. Market Attractiveness Analysis

        18.4.1. By Country

        18.4.2. By Drug

        18.4.3. By Form

        18.4.4. By Distribution Channel

    18.5. Key Market Participants - Intensity Mapping

    18.6. Drivers and Restraints - Impact Analysis

    18.7. Country Level Analysis & Forecast

        18.7.1. Australia Diabetic Macular Edema Market Analysis

            18.7.1.1. Introduction

            18.7.1.2. Market Analysis and Forecast By Market Taxonomy

                18.7.1.2.1. By Drug

                18.7.1.2.2. By Form

                18.7.1.2.3. By Distribution Channel

        18.7.2. New Zealand Diabetic Macular Edema Market Analysis

            18.7.2.1. Introduction

            18.7.2.2. Market Analysis and Forecast By Market Taxonomy

                18.7.2.2.1. By Drug

                18.7.2.2.2. By Form

                18.7.2.2.3. By Distribution Channel

19. Middle East and Africa (MEA) Diabetic Macular Edema Market Analysis 2017–2021 and Forecast 2022–2032

    19.1. Introduction

    19.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2017–2021

    19.3. Current and Future Market Size (US$ Bn) Analysis & Forecast By Market Taxonomy, 2022–2032

        19.3.1. By Country

            19.3.1.1. GCC Countries

            19.3.1.2. Turkey

            19.3.1.3. South Africa

            19.3.1.4. North Africa

            19.3.1.5. Rest of Middle East and Africa

        19.3.2. By Drug

        19.3.3. By Form

        19.3.4. By Distribution Channel

    19.4. Market Attractiveness Analysis

        19.4.1. By Country

        19.4.2. By Drug

        19.4.3. By Form

        19.4.4. By Distribution Channel

    19.5. Market Trends

    19.6. Key Market Participants - Intensity Mapping

    19.7. Drivers and Restraints - Impact Analysis

    19.8. Country Level Analysis & Forecast

        19.8.1. GCC Countries Diabetic Macular Edema Market Analysis

            19.8.1.1. Introduction

            19.8.1.2. Market Analysis and Forecast By Market Taxonomy

                19.8.1.2.1. By Drug

                19.8.1.2.2. By Form

                19.8.1.2.3. By Distribution Channel

        19.8.2. Turkey Diabetic Macular Edema Market Analysis

            19.8.2.1. Introduction

            19.8.2.2. Market Analysis and Forecast By Market Taxonomy

                19.8.2.2.1. By Drug

                19.8.2.2.2. By Form

                19.8.2.2.3. By Distribution Channel

        19.8.3. South Africa Diabetic Macular Edema Market Analysis

            19.8.3.1. Introduction

            19.8.3.2. Market Analysis and Forecast By Market Taxonomy

                19.8.3.2.1. By Drug

                19.8.3.2.2. By Form

                19.8.3.2.3. By Distribution Channel

        19.8.4. North Africa Diabetic Macular Edema Market Analysis

            19.8.4.1. Introduction

            19.8.4.2. Market Analysis and Forecast By Market Taxonomy

                19.8.4.2.1. By Drug

                19.8.4.2.2. By Form

                19.8.4.2.3. By Distribution Channel

20. Market Structure Analysis

    20.1. Market Analysis By Tier of Companies

    20.2. Market Concentration

    20.3. Market Share Analysis (%) of Top Players

    20.4. Market Presence Analysis

21. Competition Analysis

    21.1. Competition Dashboard

    21.2. Competition Benchmarking

    21.3. Competition Deep Dive

        21.3.1. Novartis AG

            21.3.1.1. Overview

            21.3.1.2. Drug Portfolio

            21.3.1.3. Sales Footprint

            21.3.1.4. Key Financials

            21.3.1.5. SWOT Analysis

            21.3.1.6. Strategic Overview

        21.3.2. Bayer AG

            21.3.2.1. Overview

            21.3.2.2. Drug Portfolio

            21.3.2.3. Sales Footprint

            21.3.2.4. Key Financials

            21.3.2.5. SWOT Analysis

            21.3.2.6. Strategic Overview

        21.3.3. Allergan Plc.

            21.3.3.1. Overview

            21.3.3.2. Drug Portfolio

            21.3.3.3. Sales Footprint

            21.3.3.4. Key Financials

            21.3.3.5. SWOT Analysis

            21.3.3.6. Strategic Overview

        21.3.4. F. Hoffman-La Roche Ltd.

            21.3.4.1. Overview

            21.3.4.2. Drug Portfolio

            21.3.4.3. Sales Footprint

            21.3.4.4. Key Financials

            21.3.4.5. SWOT Analysis

            21.3.4.6. Strategic Overview

        21.3.5. Alimera Sciences Inc.

            21.3.5.1. Overview

            21.3.5.2. Drug Portfolio

            21.3.5.3. Sales Footprint

            21.3.5.4. Key Financials

            21.3.5.5. SWOT Analysis

            21.3.5.6. Strategic Overview

        21.3.6. Valeant Pharmaceuticals International, Inc. (Bausch & Lomb Inc.)

            21.3.6.1. Overview

            21.3.6.2. Drug Portfolio

            21.3.6.3. Sales Footprint

            21.3.6.4. Key Financials

            21.3.6.5. SWOT Analysis

            21.3.6.6. Strategic Overview

        21.3.7. KalVista Pharmaceuticals

            21.3.7.1. Overview

            21.3.7.2. Drug Portfolio

            21.3.7.3. Sales Footprint

            21.3.7.4. Key Financials

            21.3.7.5. SWOT Analysis

            21.3.7.6. Strategic Overview

        21.3.8. Genentech

            21.3.8.1. Overview

            21.3.8.2. Drug Portfolio

            21.3.8.3. Sales Footprint

            21.3.8.4. Key Financials

            21.3.8.5. SWOT Analysis

            21.3.8.6. Strategic Overview

        21.3.9. Oxurion (fka ThromboGenics)

            21.3.9.1. Overview

            21.3.9.2. Drug Portfolio

            21.3.9.3. Sales Footprint

            21.3.9.4. Key Financials

            21.3.9.5. SWOT Analysis

            21.3.9.6. Strategic Overview

        21.3.10. Ocugen, Inc

            21.3.10.1. Overview

            21.3.10.2. Drug Portfolio

            21.3.10.3. Sales Footprint

            21.3.10.4. Key Financials

            21.3.10.5. SWOT Analysis

            21.3.10.6. Strategic Overview

        21.3.11. Regeneron Pharmaceuticals, Inc.

            21.3.11.1. Overview

            21.3.11.2. Drug Portfolio

            21.3.11.3. Sales Footprint

            21.3.11.4. Key Financials

            21.3.11.5. SWOT Analysis

            21.3.11.6. Strategic Overview

        21.3.12. Clearside Biomedical

            21.3.12.1. Overview

            21.3.12.2. Drug Portfolio

            21.3.12.3. Sales Footprint

            21.3.12.4. Key Financials

            21.3.12.5. SWOT Analysis

            21.3.12.6. Strategic Overview

        21.3.13. Daiichi Sankyo

            21.3.13.1. Overview

            21.3.13.2. Drug Portfolio

            21.3.13.3. Sales Footprint

            21.3.13.4. Key Financials

            21.3.13.5. SWOT Analysis

            21.3.13.6. Strategic Overview

        21.3.14. Arctic Vision

            21.3.14.1. Overview

            21.3.14.2. Drug Portfolio

            21.3.14.3. Sales Footprint

            21.3.14.4. Key Financials

            21.3.14.5. SWOT Analysis

            21.3.14.6. Strategic Overview

22. Assumptions and Acronyms Used

23. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01: Global Diabetic Macular Edema Market Analysis 2017–2021 and Forecast 2022–2032, by Drug

Table 02: Global Diabetic Macular Edema Market Analysis 2017–2021 and Forecast 2022–2032by Form

Table 03: Global Diabetic Macular Edema Market Analysis 2017–2021 and Forecast 2022–2032, by Distribution Channel

Table 04: Global Diabetic Macular Edema Market Analysis 2017–2021 and Forecast 2022–2032, by Region

Table 05: North America Diabetic Macular Edema Market Value (US$ Bn) Analysis 2017–2021 and Forecast 2022–2032, by Country

Table 06: North America Diabetic Macular Edema Market Value (US$ Bn) Analysis 2017–2021 and Forecast 2022–2032, by Drug

Table 07: North America Diabetic Macular Edema Market Value (US$ Bn) Analysis 2017–2021 and Forecast 2022–2032, by Form

Table 08: North America Diabetic Macular Edema Market Value (US$ Bn) Analysis 2017–2021 and Forecast 2022–2032, by Distribution Channel

Table 09: Latin America Diabetic Macular Edema Market Value (US$ Bn) Analysis 2017–2021 and Forecast 2022–2032, by Country

Table 10: Latin America Diabetic Macular Edema Market Value (US$ Bn) Analysis 2017–2021 and Forecast 2022–2032, by Drug

Table 11: Latin America Diabetic Macular Edema Market Value (US$ Bn) Analysis 2017–2021 and Forecast 2022–2032, by Form

Table 12: Latin America Diabetic Macular Edema Market Value (US$ Bn) Analysis 2017–2021 and Forecast 2022–2032, by Distribution Channel

Table 13: Europe Diabetic Macular Edema Market Value (US$ Bn) Analysis 2017–2021 and Forecast 2022–2032, by Country

Table 14: Europe Diabetic Macular Edema Market Value (US$ Bn) Analysis 2017–2021 and Forecast 2022–2032, by Drug

Table 15: Europe Diabetic Macular Edema Market Analysis 2017–2021 and Forecast 2022–2032by Form

Table 16: Europe Diabetic Macular Edema Market Value (US$ Bn) Analysis 2017–2021 and Forecast 2022–2032, by Distribution Channel

Table 17: East Asia Diabetic Macular Edema Market Value (US$ Bn) Analysis 2017–2021 and Forecast 2022–2032, by Country

Table 18: East Asia Diabetic Macular Edema Market Value (US$ Bn) Analysis 2017–2021 and Forecast 2022–2032, by Drug

Table 19: East Asia Diabetic Macular Edema Market Value (US$ Bn) Analysis 2017–2021 and Forecast 2022–2032, by Form

Table 20: East Asia Diabetic Macular Edema Market Value (US$ Bn) Analysis 2017–2021 and Forecast 2022–2032, by Distribution Channel

Table 21: South Asia Diabetic Macular Edema Market Value (US$ Bn) Analysis 2017–2021 and Forecast 2022–2032, by Country

Table 22: South Asia Diabetic Macular Edema Market Value (US$ Bn) Analysis 2017–2021 and Forecast 2022–2032, by Drug

Table 23: South Asia Diabetic Macular Edema Market Value (US$ Bn) Analysis 2017–2021 and Forecast 2022–2032, by Form

Table 24: South Asia Diabetic Macular Edema Market Value (US$ Bn) Analysis 2017–2021 and Forecast 2022–2032, by Distribution Channel

Table 25: Oceania Diabetic Macular Edema Market Value (US$ Bn) Analysis 2017–2021 and Forecast 2022–2032, by Country

Table 26: Oceania Diabetic Macular Edema Market Value (US$ Bn) Analysis 2017–2021 and Forecast 2022–2032, by Drug

Table 27: Oceania Diabetic Macular Edema Market Analysis 2017–2021 and Forecast 2022–2032by Form

Table 28: Oceania Diabetic Macular Edema Market Value (US$ Bn) Analysis 2017–2021 and Forecast 2022–2032, by Distribution Channel

Table 29: Middle East & Africa Diabetic Macular Edema Market Value (US$ Bn) Analysis 2017–2021 and Forecast 2022–2032, by Country

Table 30: Middle East & Africa Diabetic Macular Edema Market Value (US$ Bn) Analysis 2017–2021 and Forecast 2022–2032, by Drug

Table 31: Middle East & Africa Diabetic Macular Edema Market Analysis 2017–2021 and Forecast 2022–2032by Form

Table 32: Middle East & Africa Diabetic Macular Edema Market Value (US$ Bn) Analysis 2017–2021 and Forecast 2022–2032, by Distribution Channel

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global Diabetic Macular Edema Market Value (US$ Bn) Analysis, 2017–2021

Figure 02: Global Diabetic Macular Edema Market Forecast & Y-o-Y Growth, 2022–2032

Figure 03: Global Diabetic Macular Edema Market Absolute $ Opportunity (US$ Bn) Analysis, 2021–2032

Figure 04: Global Diabetic Macular Edema Market Value Share (%) Analysis 2022 and 2032, by Drug

Figure 05: Global Diabetic Macular Edema Market Y-o-Y Growth (%) Analysis 2021-2032, by Drug

Figure 06: Global Diabetic Macular Edema Market Attractiveness Analysis 2022–2032, by Drug

Figure 07: Global Diabetic Macular Edema Market Value Share (%) Analysis 2022 and 2032, by Form

Figure 08: Global Diabetic Macular Edema Market Y-o-Y Growth (%) Analysis 2021-2032, by Form

Figure 09: Global Diabetic Macular Edema Market Attractiveness Analysis 2022–2032, by Form

Figure 10: Global Diabetic Macular Edema Market Value Share (%) Analysis 2022 and 2032, by Distribution Channel

Figure 11: Global Diabetic Macular Edema Market Y-o-Y Growth (%) Analysis 2021-2032, by Distribution Channel

Figure 12: Global Diabetic Macular Edema Market Attractiveness Analysis 2022–2032, by Distribution Channel

Figure 13: Global Diabetic Macular Edema Market Value Share (%) Analysis 2022 and 2032, by Region

Figure 14: Global Diabetic Macular Edema Market Y-o-Y Growth (%) Analysis 2021-2032, by Region

Figure 15: Global Diabetic Macular Edema Market Attractiveness Analysis 2022–2032, by Region

Figure 16: North America Diabetic Macular Edema Market Value (US$ Bn) Analysis, 2017–2021

Figure 17: North America Diabetic Macular Edema Market Value (US$ Bn) Forecast, 2022-2032

Figure 18: North America Diabetic Macular Edema Market Value Share, by Drug (2022 E)

Figure 19: North America Diabetic Macular Edema Market Value Share, by Form (2022 E)

Figure 20: North America Diabetic Macular Edema Market Value Share, by Distribution Channel (2022 E)

Figure 21: North America Diabetic Macular Edema Market Value Share, by Country (2022 E)

Figure 22: North America Diabetic Macular Edema Market Attractiveness Analysis by Drug, 2022–2032

Figure 23: North America Diabetic Macular Edema Market Attractiveness Analysis by Form, 2022–2032

Figure 24: North America Diabetic Macular Edema Market Attractiveness Analysis by Distribution Channel, 2022–2032

Figure 25: North America Diabetic Macular Edema Market Attractiveness Analysis by Country, 2022–2032

Figure 26: U.S. Diabetic Macular Edema Market Value Proportion Analysis, 2021

Figure 27: Global Vs. U.S. Growth Comparison

Figure 28: U.S. Diabetic Macular Edema Market Share Analysis (%) by Drug, 2021 & 2032

Figure 29: U.S. Diabetic Macular Edema Market Share Analysis (%) by Form, 2021 & 2032

Figure 30: U.S. Diabetic Macular Edema Market Share Analysis (%) by Distribution Channel, 2021 & 2032

Figure 31: Canada Diabetic Macular Edema Market Value Proportion Analysis, 2021

Figure 32: Global Vs. Canada. Growth Comparison

Figure 33: Canada Diabetic Macular Edema Market Share Analysis (%) by Drug, 2021 & 2032

Figure 34: Canada Diabetic Macular Edema Market Share Analysis (%) by Form, 2021 & 2032

Figure 35: Canada Diabetic Macular Edema Market Share Analysis (%) by Distribution Channel, 2021 & 2032

Figure 36: Latin America Diabetic Macular Edema Market Value (US$ Bn) Analysis, 2017–2021

Figure 37: Latin America Diabetic Macular Edema Market Value (US$ Bn) Forecast, 2022-2032

Figure 38: Latin America Diabetic Macular Edema Market Value Share, by Drug (2022 E)

Figure 39: Latin America Diabetic Macular Edema Market Value Share, by Form (2022 E)

Figure 40: Latin America Diabetic Macular Edema Market Value Share, by Distribution Channel (2022 E)

Figure 41: Latin America Diabetic Macular Edema Market Value Share, by Country (2022 E)

Figure 42: Latin America Diabetic Macular Edema Market Attractiveness Analysis by Drug, 2022–2032

Figure 43: Latin America Diabetic Macular Edema Market Attractiveness Analysis by Form, 2022–2032

Figure 44: Latin America Diabetic Macular Edema Market Attractiveness Analysis by Distribution Channel, 2022–2032

Figure 45: Latin America Diabetic Macular Edema Market Attractiveness Analysis by Country, 2022–2032

Figure 46: Mexico Diabetic Macular Edema Market Value Proportion Analysis, 2021

Figure 47: Global Vs Mexico Growth Comparison

Figure 48: Mexico Diabetic Macular Edema Market Share Analysis (%) by Drug, 2021 & 2032

Figure 49: Mexico Diabetic Macular Edema Market Share Analysis (%) by Form, 2021 & 2032

Figure 50: Mexico Diabetic Macular Edema Market Share Analysis (%) by Distribution Channel, 2021 & 2032

Figure 51: Brazil Diabetic Macular Edema Market Value Proportion Analysis, 2021

Figure 52: Global Vs. Brazil. Growth Comparison

Figure 53: Brazil Diabetic Macular Edema Market Share Analysis (%) by Drug, 2021 & 2032

Figure 54: Brazil Diabetic Macular Edema Market Share Analysis (%) by Form, 2021 & 2032

Figure 55: Brazil Diabetic Macular Edema Market Share Analysis (%) by Distribution Channel, 2021 & 2032

Figure 56: Argentina Diabetic Macular Edema Market Value Proportion Analysis, 2021

Figure 57: Global Vs Argentina Growth Comparison

Figure 58: Argentina Diabetic Macular Edema Market Share Analysis (%) by Drug, 2021 & 2032

Figure 59: Argentina Diabetic Macular Edema Market Share Analysis (%) by Form, 2021 & 2032

Figure 60: Argentina Diabetic Macular Edema Market Share Analysis (%) by Distribution Channel, 2021 & 2032

Figure 61: Europe Diabetic Macular Edema Market Value (US$ Bn) Analysis, 2017–2021

Figure 62: Europe Diabetic Macular Edema Market Value (US$ Bn) Forecast, 2022-2032

Figure 63: Europe Diabetic Macular Edema Market Value Share, by Drug (2022 E)

Figure 64: Europe Diabetic Macular Edema Market Value Share, by Form (2022 E)

Figure 65: Europe Diabetic Macular Edema Market Value Share, by Distribution Channel (2022 E)

Figure 66: Europe Diabetic Macular Edema Market Value Share, by Country (2022 E)

Figure 67: Europe Diabetic Macular Edema Market Attractiveness Analysis by Drug, 2022–2032

Figure 68: Europe Diabetic Macular Edema Market Attractiveness Analysis by Form, 2022–2032

Figure 69: Europe Diabetic Macular Edema Market Attractiveness Analysis by Distribution Channel, 2022–2032

Figure 70: Europe Diabetic Macular Edema Market Attractiveness Analysis by Country, 2022–2032

Figure 71: UK Diabetic Macular Edema Market Value Proportion Analysis, 2021

Figure 72: Global Vs. UK Growth Comparison

Figure 73: UK Diabetic Macular Edema Market Share Analysis (%) by Drug, 2021 & 2032

Figure 74: UK Diabetic Macular Edema Market Share Analysis (%) by Form, 2021 & 2032

Figure 75: UK Diabetic Macular Edema Market Share Analysis (%) by Distribution Channel, 2021 & 2032

Figure 76: Germany Diabetic Macular Edema Market Value Proportion Analysis, 2021

Figure 77: Global Vs. Germany Growth Comparison

Figure 78: Germany Diabetic Macular Edema Market Share Analysis (%) by Drug, 2021 & 2032

Figure 79: Germany Diabetic Macular Edema Market Share Analysis (%) by Form, 2021 & 2032

Figure 80: Germany Diabetic Macular Edema Market Share Analysis (%) by Distribution Channel, 2021 & 2032

Figure 81: Italy Diabetic Macular Edema Market Value Proportion Analysis, 2021

Figure 82: Global Vs. Italy Growth Comparison

Figure 83: Italy Diabetic Macular Edema Market Share Analysis (%) by Drug, 2021 & 2032

Figure 84: Italy Diabetic Macular Edema Market Share Analysis (%) by Form, 2021 & 2032

Figure 85: Italy Diabetic Macular Edema Market Share Analysis (%) by Distribution Channel, 2021 & 2032

Figure 86: France Diabetic Macular Edema Market Value Proportion Analysis, 2021

Figure 87: Global Vs France Growth Comparison

Figure 88: France Diabetic Macular Edema Market Share Analysis (%) by Drug, 2021 & 2032

Figure 89: France Diabetic Macular Edema Market Share Analysis (%) by Form, 2021 & 2032

Figure 90: France Diabetic Macular Edema Market Share Analysis (%) by Distribution Channel, 2021 & 2032

Figure 91: Spain Diabetic Macular Edema Market Value Proportion Analysis, 2021

Figure 92: Global Vs Spain Growth Comparison

Figure 93: Spain Diabetic Macular Edema Market Share Analysis (%) by Drug, 2021 & 2032

Figure 94: Spain Diabetic Macular Edema Market Share Analysis (%) by Form, 2021 & 2032

Figure 95: Spain Diabetic Macular Edema Market Share Analysis (%) by Distribution Channel, 2021 & 2032

Figure 96: Russia Diabetic Macular Edema Market Value Proportion Analysis, 2021

Figure 97: Global Vs Russia Growth Comparison

Figure 98: Russia Diabetic Macular Edema Market Share Analysis (%) by Drug, 2021 & 2032

Figure 99: Russia Diabetic Macular Edema Market Share Analysis (%) by Form, 2021 & 2032

Figure 100: Russia Diabetic Macular Edema Market Share Analysis (%) by Distribution Channel, 2021 & 2032

Figure 101: BENELUX Diabetic Macular Edema Market Value Proportion Analysis, 2021

Figure 102: Global Vs BENELUX Growth Comparison

Figure 103: BENELUX Diabetic Macular Edema Market Share Analysis (%) by Drug, 2021 & 2032

Figure 104: BENELUX Diabetic Macular Edema Market Share Analysis (%) by Form, 2021 & 2032

Figure 105: BENELUX Diabetic Macular Edema Market Share Analysis (%) by Distribution Channel, 2021 & 2032

Figure 106: East Asia Diabetic Macular Edema Market Value (US$ Bn) Analysis, 2017–2021

Figure 107: East Asia Diabetic Macular Edema Market Value (US$ Bn) Forecast, 2022-2032

Figure 108: East Asia Diabetic Macular Edema Market Value Share, by Drug (2022 E)

Figure 109: East Asia Diabetic Macular Edema Market Value Share, by Form (2022 E)

Figure 110: East Asia Diabetic Macular Edema Market Value Share, by Distribution Channel (2022 E)

Figure 111: East Asia Diabetic Macular Edema Market Value Share, by Country (2022 E)

Figure 112: East Asia Diabetic Macular Edema Market Attractiveness Analysis by Drug, 2022–2032

Figure 113: East Asia Diabetic Macular Edema Market Attractiveness Analysis by Form, 2022–2032

Figure 114: East Asia Diabetic Macular Edema Market Attractiveness Analysis by Distribution Channel, 2022–2032

Figure 115: East Asia Diabetic Macular Edema Market Attractiveness Analysis by Country, 2022–2032

Figure 116: China Diabetic Macular Edema Market Value Proportion Analysis, 2021

Figure 117: Global Vs. China Growth Comparison

Figure 118: China Diabetic Macular Edema Market Share Analysis (%) by Drug, 2021 & 2032

Figure 119: China Diabetic Macular Edema Market Share Analysis (%) by Form, 2021 & 2032

Figure 120: China Diabetic Macular Edema Market Share Analysis (%) by Distribution Channel, 2021 & 2032

Figure 121: Japan Diabetic Macular Edema Market Value Proportion Analysis, 2021

Figure 122: Global Vs. Japan Growth Comparison

Figure 123: Japan Diabetic Macular Edema Market Share Analysis (%) by Drug, 2021 & 2032

Figure 124: Japan Diabetic Macular Edema Market Share Analysis (%) by Form, 2021 & 2032

Figure 125: Japan Diabetic Macular Edema Market Share Analysis (%) by Distribution Channel, 2021 & 2032

Figure 126: South Korea Diabetic Macular Edema Market Value Proportion Analysis, 2021

Figure 127: Global Vs South Korea Growth Comparison

Figure 128: South Korea Diabetic Macular Edema Market Share Analysis (%) by Drug, 2021 & 2032

Figure 129: South Korea Diabetic Macular Edema Market Share Analysis (%) by Form, 2021 & 2032

Figure 130: South Korea Diabetic Macular Edema Market Share Analysis (%) by Distribution Channel, 2021 & 2032

Figure 131: South Asia Diabetic Macular Edema Market Value (US$ Bn) Analysis, 2017–2021

Figure 132: South Asia Diabetic Macular Edema Market Value (US$ Bn) Forecast, 2022-2032

Figure 133: South Asia Diabetic Macular Edema Market Value Share, by Drug (2022 E)

Figure 134: South Asia Diabetic Macular Edema Market Value Share, by Form (2022 E)

Figure 135: South Asia Diabetic Macular Edema Market Value Share, by Distribution Channel (2022 E)

Figure 136: South Asia Diabetic Macular Edema Market Value Share, by Country (2022 E)

Figure 137: South Asia Diabetic Macular Edema Market Attractiveness Analysis by Drug, 2022–2032

Figure 138: South Asia Diabetic Macular Edema Market Attractiveness Analysis by Form, 2022–2032

Figure 139: South Asia Diabetic Macular Edema Market Attractiveness Analysis by Distribution Channel, 2022–2032

Figure 140: South Asia Diabetic Macular Edema Market Attractiveness Analysis by Country, 2022–2032

Figure 141: India Diabetic Macular Edema Market Value Proportion Analysis, 2021

Figure 142: Global Vs. India Growth Comparison

Figure 143: India Diabetic Macular Edema Market Share Analysis (%) by Drug, 2021 & 2032

Figure 144: India Diabetic Macular Edema Market Share Analysis (%) by Form, 2021 & 2032

Figure 145: India Diabetic Macular Edema Market Share Analysis (%) by Distribution Channel, 2021 & 2032

Figure 146: Indonesia Diabetic Macular Edema Market Value Proportion Analysis, 2021

Figure 147: Global Vs. Indonesia Growth Comparison

Figure 148: Indonesia Diabetic Macular Edema Market Share Analysis (%) by Drug, 2021 & 2032

Figure 149: Indonesia Diabetic Macular Edema Market Share Analysis (%) by Form, 2021 & 2032

Figure 150: Indonesia Diabetic Macular Edema Market Share Analysis (%) by Distribution Channel, 2021 & 2032

Figure 151: Malaysia Diabetic Macular Edema Market Value Proportion Analysis, 2021

Figure 152: Global Vs. Malaysia Growth Comparison

Figure 153: Malaysia Diabetic Macular Edema Market Share Analysis (%) by Drug, 2021 & 2032

Figure 154: Malaysia Diabetic Macular Edema Market Share Analysis (%) by Form, 2021 & 2032

Figure 155: Malaysia Diabetic Macular Edema Market Share Analysis (%) by Distribution Channel, 2021 & 2032

Figure 156: Thailand Diabetic Macular Edema Market Value Proportion Analysis, 2021

Figure 157: Global Vs. Thailand Growth Comparison

Figure 158: Thailand Diabetic Macular Edema Market Share Analysis (%) by Drug, 2021 & 2032

Figure 159: Thailand Diabetic Macular Edema Market Share Analysis (%) by Form, 2021 & 2032

Figure 160: Thailand Diabetic Macular Edema Market Share Analysis (%) by Distribution Channel, 2021 & 2032

Figure 161: Oceania Diabetic Macular Edema Market Value (US$ Bn) Analysis, 2017–2021

Figure 162: Oceania Diabetic Macular Edema Market Value (US$ Bn) Forecast, 2022-2032

Figure 163: Oceania Diabetic Macular Edema Market Value Share, by Drug (2022 E)

Figure 164: Oceania Diabetic Macular Edema Market Value Share, by Form (2022 E)

Figure 165: Oceania Diabetic Macular Edema Market Value Share, by Distribution Channel (2022 E)

Figure 166: Oceania Diabetic Macular Edema Market Value Share, by Country (2022 E)

Figure 167: Oceania Diabetic Macular Edema Market Attractiveness Analysis by Drug, 2022–2032

Figure 168: Oceania Diabetic Macular Edema Market Attractiveness Analysis by Form, 2022–2032

Figure 169: Oceania Diabetic Macular Edema Market Attractiveness Analysis by Distribution Channel, 2022–2032

Figure 170: Oceania Diabetic Macular Edema Market Attractiveness Analysis by Country, 2022–2032

Figure 171: Australia Diabetic Macular Edema Market Value Proportion Analysis, 2021

Figure 172: Global Vs. Australia Growth Comparison

Figure 173: Australia Diabetic Macular Edema Market Share Analysis (%) by Drug, 2021 & 2032

Figure 174: Australia Diabetic Macular Edema Market Share Analysis (%) by Form, 2021 & 2032

Figure 175: Australia Diabetic Macular Edema Market Share Analysis (%) by Distribution Channel, 2021 & 2032

Figure 176: New Zealand Diabetic Macular Edema Market Value Proportion Analysis, 2021

Figure 177: Global Vs New Zealand Growth Comparison

Figure 178: New Zealand Diabetic Macular Edema Market Share Analysis (%) by Drug, 2021 & 2032

Figure 179: New Zealand Diabetic Macular Edema Market Share Analysis (%) by Form, 2021 & 2032

Figure 180: New Zealand Diabetic Macular Edema Market Share Analysis (%) by Distribution Channel, 2021 & 2032

Figure 181: Middle East & Africa Diabetic Macular Edema Market Value (US$ Bn) Analysis, 2017–2021

Figure 182: Middle East & Africa Diabetic Macular Edema Market Value (US$ Bn) Forecast, 2022-2032

Figure 183: Middle East & Africa Diabetic Macular Edema Market Value Share, by Drug (2022 E)

Figure 184: Middle East & Africa Diabetic Macular Edema Market Value Share, by Form (2022 E)

Figure 185: Middle East & Africa Diabetic Macular Edema Market Value Share, by Distribution Channel (2022 E)

Figure 186: Middle East & Africa Diabetic Macular Edema Market Value Share, by Country (2022 E)

Figure 187: Middle East & Africa Diabetic Macular Edema Market Attractiveness Analysis by Drug, 2022–2032

Figure 188: Middle East & Africa Diabetic Macular Edema Market Attractiveness Analysis by Form, 2022–2032

Figure 189: Middle East & Africa Diabetic Macular Edema Market Attractiveness Analysis by Distribution Channel, 2022–2032

Figure 190: Middle East & Africa Diabetic Macular Edema Market Attractiveness Analysis by Country, 2022–2032

Figure 191: GCC Countries Diabetic Macular Edema Market Value Proportion Analysis, 2021

Figure 192: Global Vs GCC Countries Growth Comparison

Figure 193: GCC Countries Diabetic Macular Edema Market Share Analysis (%) by Drug, 2021 & 2032

Figure 194: GCC Countries Diabetic Macular Edema Market Share Analysis (%) by Form, 2021 & 2032

Figure 195: GCC Countries Diabetic Macular Edema Market Share Analysis (%) by Distribution Channel, 2021 & 2032

Figure 196: Turkey Diabetic Macular Edema Market Value Proportion Analysis, 2021

Figure 197: Global Vs. Turkey Growth Comparison

Figure 198: Turkey Diabetic Macular Edema Market Share Analysis (%) by Drug, 2021 & 2032

Figure 199: Turkey Diabetic Macular Edema Market Share Analysis (%) by Form, 2021 & 2032

Figure 200: Turkey Diabetic Macular Edema Market Share Analysis (%) by Distribution Channel, 2021 & 2032

Figure 201: South Africa Diabetic Macular Edema Market Value Proportion Analysis, 2021

Figure 202: Global Vs. South Africa Growth Comparison

Figure 203: South Africa Diabetic Macular Edema Market Share Analysis (%) by Drug, 2021 & 2032

Figure 204: South Africa Diabetic Macular Edema Market Share Analysis (%) by Form, 2021 & 2032

Figure 205: South Africa Diabetic Macular Edema Market Share Analysis (%) by Distribution Channel, 2021 & 2032

Figure 206: North Africa Diabetic Macular Edema Market Value Proportion Analysis, 2021

Figure 207: Global Vs North Africa Growth Comparison

Figure 208: North Africa Diabetic Macular Edema Market Share Analysis (%) by Drug, 2021 & 2032

Figure 209: North Africa Diabetic Macular Edema Market Share Analysis (%) by Form, 2021 & 2032

Figure 210: North Africa Diabetic Macular Edema Market Share Analysis (%) by Distribution Channel, 2021 & 2032

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Retinal Biologics Market

Published : March 2022

Healthcare

Corneal Ulcer Treatment Market

Published : February 2020

Healthcare

Diabetes Care Devices Market

Published : January 1970

Industrial Automation

Industrial Wireless Broken Signal Solutions Market

Published : January 1970

Google translate

Diabetic Macular Edema Market